Cervical cancer vaccine could cut mortality by three quarters
A vaccine which protects against the infection that causes cervical cancer could cut the mortality rate of the disease by 75 per cent, its manufacturers have claimed.
Around 1,093 women currently die every year from cervical cancer, a rate which the maker GlaxoSmithKline believes could fall to under 300.
And the number of cervical cancer cases overall would also fall, from 2,841 to 682, said the company, in a report delivered to a conference in Prague.
The estimates depend on a 100 per cent take up rate of the vaccine, a figure that GlaxoSmithKline concedes is unlikely.
Even with an 80 per cent take up rate the company believes that the number of cervical cancer fatalities could be reduced by 61 per cent, however.
GlaxoSmithKline is one of two companies developing a vaccine against the human papilloma virus (HPV), a sexually transmitted disease which causes most cervical cancers.
The report was delivered at the International Papilloma Conference in the Czech Republic.
Find out more about cervical cancer